Tuberous sclerosis complex and myocardial fat‐containing lesions: a report of four cases
EB Winterkorn,JD Dodd,I. Inglessis,G. Holmvang,EA Thiele
DOI: https://doi.org/10.1111/j.1399-0004.2007.00775.x
2007-04-01
Clinical Genetics
Abstract:To the Editor: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with an incidence of 1/6000 (1). Mutations in either TSC1 (MIM 191100) or TSC2 (MIM *191902) lead to multiple hamartomatous growths (2). We reported a series of four patients with TSC and renal Angiomyolipomas (AMLs) who developed intramyocardial lipomatous lesions. Patient A, a 48-year-old man with a mild phenotype, required renal AML embolization. Pre-operative cardiac evaluation revealed two fat-density myocardial lesions (Fig. 1A–C). Patient B, a 34-year-old man with multiorgan involvement, underwent nephrectomy after failed re-embolization of a renal AML. He re-presented with dyspnea and chest pain, attributed to childhood subaortic stenosis repair. Cardiac computed tomography (CT) showed three myocardial fat-containing lesions (Fig. 1D). He underwent aortic root replacement without further complaint. Patient C, a 38-year-old woman, has epilepsy, and underwent nephrectomy for hemorrhagic AML. Routine chest CT revealed pulmonary lymphangioleiomyomatosis (LAM) and multiple myocardial fat-density lesions (Fig. 1E). Patient D, a 38-year-old woman, required partial nephrectomy for hemorrhagic AML. Routine chest CT revealed LAM, multiple ventricular fat-density lesions, hepatic AMLs, and mediastinal lymphadenopathy (Fig. 1F,G). None of these patients was known to have rhabdomyomas and all have had Electrocardiograms without signs of arrhythmia. The lesions’ locations and fatty appearance were not consistent with myxomas, hemangiomas, or rhabdomyomas. Rhabdomyomas (hamartomas found in 50% of individuals with TSC) regress during childhood; therefore, the remaining differential diagnosis was intracardiac lipomas or AMLs (1, 3–5). Cardiac lipomas, 4% of benign cardiac tumors, are encapsulated fatty tumors, which occasionally contain vascular and muscle tissue; longterm prognosis is good (4, 8, 7). Lipomas are distinguishable on magnetic resonance imaging but difficult to differentiate from AMLs without histology (4, 6, 7). They are usually solitary, although all three reported cases of multiple cardiac lipomas were in individuals with TSC; no histopathologic distinction from AML was made in those cases (8). AMLs are benign tumors of muscle, fat, and vasculature, found most commonly in the kidneys. Renal AMLs occur in 50–80% of individuals with TSC and are a major cause of morbidity mainly because of intralesional hemorrhage (3, 9). Extrarenal AMLs are rare, but occur most commonly in TSC (1, 10, 11). They are less vascular and therefore less prone to hemorrhage (1). We found seven reports of cardiac AMLs – all solitary non-ventricular lesions. Two were primary cardiac lesions in patients without TSC or AML. Five had renal AMLs with tumor extension into the Inferior Vena Cava and right atrium. Two reports specify negative testing for TSC; three make no mention of TSC (11, 12). Two mechanisms have been proposed for hamartomatous growth in TSC. First, the second-hit hypothesis suggests that a second deactivating mutation at either TSC locus results in disorganized cellular growth and differentiation, leading to tumor formation. This is supported by observed loss of heterozygosity (LOH) at TSC loci in renal tumors of patients with TSC (13, 14). Second, non-malignant metastasis suggests histologically that benign cells migrate between organs. This may explain the association between AML and LAM in TSC (1, 15). LAM occurs in 26–40% of women with TSC, and is always associated with AML (1, 15). Identical LOH mutations have been found in AMLs and LAM of individual patients, and recurrent LAM was reported in a lung transplant recipient with concurrent AML (1, 14, 15). All our patients had multiple renal AMLs. Identical second-hit mutations in renal and cardiac lesions would support non-malignant metastasis.